{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:31:32Z","timestamp":1788280292289,"version":"build-2803163510"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,28]]},"DOI":"10.7759\/cureus.42603","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T11:03:08Z","timestamp":1690542188000},"source":"Crossref","is-referenced-by-count":4,"title":["Identifying the Toxidrome of Ivermectin Toxicity"],"prefix":"10.7759","author":[{"given":"Jon Stewart H","family":"Dy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan  N","family":"Juangco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Antiprotozoal drugs","author":"Katzung BG","year":"2021","unstructured":"Katzung BG, Masters SB, Trevor AJ. Antiprotozoal drugs. Basic & Clinical Pharmacology. McGraw-Hill, United States of America; 2021. 52:915-36."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12644","article-title":"A systematic review of experimental evidence for antiviral effects of ivermectin and an in silico analysis of ivermectin's possible mode of action against SARS-CoV-2","volume":"35","author":"Kinobe RT","year":"2021","unstructured":"Kinobe RT, Owens L. A systematic review of experimental evidence for antiviral effects of ivermectin and an in silico analysis of ivermectin's possible mode of action against SARS-CoV-2. Fundam Clin Pharmacol. 2021, 35:260-76. 10.1111\/fcp.12644","journal-title":"Fundam Clin Pharmacol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-2879768\/v1","article-title":"O. volvulus microfilariae in the anterior chambers of the eye and ocular adverse events after a single dose of 8 mg moxidectin or 150 \u00b5g\/kg ivermectin: Results of a randomized double-blind Phase 3 trial in the Democratic Republic of the Congo, Ghana and Liberia [PREPRINT]","author":"Kanza EM","year":"2023","unstructured":"Kanza EM, Nyathirombo A, Larbelee JP, et al.. O. volvulus microfilariae in the anterior chambers of the eye and ocular adverse events after a single dose of 8 mg moxidectin or 150 \u00b5g\/kg ivermectin: Results of a randomized double-blind Phase 3 trial in the Democratic Republic of the Congo, Ghana and Liberia [PREPRINT]. 2023, 1-26. 10.21203\/rs.3.rs-2879768\/v1"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1917344","article-title":"Serious ivermectin toxicity and human ABCB1 nonsense mutations","volume":"383","author":"Baudou E","year":"2020","unstructured":"Baudou E, Lespine A, Durrieu G, Andr\u00e9 F, Gandia P, Durand C, Cunat S. Serious ivermectin toxicity and human ABCB1 nonsense mutations. N Engl J Med. 2020, 383:787-9. 10.1056\/NEJMc1917344","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.17-0042","article-title":"Serious neurological adverse events after ivermectin-do they occur beyond the indication of onchocerciasis?","volume":"98","author":"Chandler RE","year":"2018","unstructured":"Chandler RE. Serious neurological adverse events after ivermectin-do they occur beyond the indication of onchocerciasis?. Am J Trop Med Hyg. 2018, 98:382-8. 10.4269\/ajtmh.17-0042","journal-title":"Am J Trop Med Hyg"},{"key":"ref6","article-title":"","author":"Ropper A","year":"2019","unstructured":"Ropper A, Samuels M, Klein J, et al.. Adams and Victor's Principles of Neurology. McGraw-Hill, United States of America; 2019. 41:1209-50."},{"key":"ref7","unstructured":"COVID-19 encephalopathy. (2020). Accessed. November 10, 2021: https:\/\/www.uptodate.com\/contents\/covid-19-neurologic-complications-and-management-of-neurologic-conditions."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2883-2-S1-S8","article-title":"Ivermectin: does P-glycoprotein play a role in neurotoxicity?","volume":"2","author":"Edwards G","year":"2003","unstructured":"Edwards G. Ivermectin: does P-glycoprotein play a role in neurotoxicity?. Filaria J. 2003, 2:S8. 10.1186\/1475-2883-2-S1-S8","journal-title":"Filaria J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009354","article-title":"Serious adverse reactions associated with ivermectin: a systematic pharmacovigilance study in sub-Saharan Africa and in the rest of the World","volume":"15","author":"Campillo JT","year":"2021","unstructured":"Campillo JT, Boussinesq M, Bertout S, Faillie JL, Chesnais CB. Serious adverse reactions associated with ivermectin: a systematic pharmacovigilance study in sub-Saharan Africa and in the rest of the World. PLoS Negl Trop Dis. 2021, 15:e0009354. 10.1371\/journal.pntd.0009354","journal-title":"PLoS Negl Trop Dis"},{"key":"ref10","unstructured":"National Poison Control and Information Service. (2021). Accessed. November 10, 2021: https:\/\/www.upm.edu.ph\/node\/1293."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/170227-identifying-the-toxidrome-of-ivermectin-toxicity","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:01:28Z","timestamp":1707508888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/170227-identifying-the-toxidrome-of-ivermectin-toxicity"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,28]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.42603","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,28]]}}}